You must be of legal age to consume cannabis in your province of residence to enter our website. By clicking ‘Enter’, you confirm that you are of legal age to consume cannabis in your province of residence (19+, 18+ in AB or QC).
By entering this site, you agree to our Terms and Conditions & Privacy Policy
Northern Green Sciences (NGS) incorporated in 2017, is a wholly-owned subsidiary of licensed producer Northern Green Canada. As the owner of all research and development initiatives, NGS’ mission is to validate cannabis as a viable medical alternative to the use of allopathic medicine.
Through comprehensive clinical trials, conducted under federal regulations and approved by the Research Ethics Board (REB) in Canada, our goal is to initiate the foundation for NGS to become a pure pharmaceutical entity. NGS seeks to promote evidenced-based understanding of cannabis with the desired outcome to obtain a Drug Identification Number (DIN) for cannabis-based products.
See Our Work
Oversight of all NGS research and development will be managed by our expert medical committee, lead by the esteemed Dr. Raphel Mechoulam. Dr. Mechoulam is recognized as a leader in the medicinal cannabis field, and is a pioneer in THC and CBD research.
NGS is aligned with the sharpest minds in the field of scientific medicinal cannabis research whose visions and objectives are aligned to develop the most advanced medical delivery systems to provide consistent and customized dosed medication.
Special Advisor, R&D Oversight
Doctor of Emergency Medicine
Aventura Hospital, Florida
Chief Physician
Ontario Ministry of Labour
Assistant Clinical Professor
Dept. of Internal Medicine, McMaster University
Chairman of the Committee, R&D Director
NGS
NGS’ initial clinical study of Cannabis for Opioid Substitution was approved by the Canadian REB (Research Ethics Board) and initiated in 2017. Currently in Phase 2, it is anticipated that Phase 3 of the study will begin in early 2020. In addition to the opioid substitution study, NGS has embarked on the development of scientific based solutions for pain management with the use of medicinal cannabis and various illness indications such as:
Phase 2 – Q4 2019
Phase 2 – Q4 2019
Phase 3 – Q1 2020
At NGS our top priority is to improve the quality of patients’ lives without unnecessary negative side effects. Through ongoing research, studies and clinical trials, our aim is to be the established authority in Canadian cannabis research.
Passion, dedication and ingenuity will continue to drive the advancement of the science of cannabis and are the tenets of NGS.
